424 related articles for article (PubMed ID: 29386072)
21. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R; Zinzani PL; Lee HJ; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Lin J; Kim E; Nahar A; Balakumaran A; Moskowitz CH
Blood; 2019 Oct; 134(14):1144-1153. PubMed ID: 31409671
[TBL] [Abstract][Full Text] [Related]
22. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract][Full Text] [Related]
23. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.
Lee JY; Kwon JH; Hur JY; Yi JH; Lee JH; Cho H; Do YR; Jo JC; Kang HJ; Koh Y; Lee WS; Lim SN; Yoon SE; Kim SJ; Lee JO
Cancer Res Treat; 2024 Apr; 56(2):681-687. PubMed ID: 37946408
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
26. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract][Full Text] [Related]
27. Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.
Ayers M; Nebozhyn M; Cristescu R; McClanahan TK; Perini R; Rubin E; Cheng JD; Kaufman DR; Loboda A
Clin Cancer Res; 2019 Mar; 25(5):1564-1573. PubMed ID: 30442684
[TBL] [Abstract][Full Text] [Related]
28. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
Song HN; Kang MG; Park JR; Hwang JY; Kang JH; Lee WS; Lee GW
Cancer Res Treat; 2018 Oct; 50(4):1458-1461. PubMed ID: 29361819
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
Cho J; Kim HS; Ku BM; Choi YL; Cristescu R; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2019 Aug; 37(24):2162-2170. PubMed ID: 29906252
[TBL] [Abstract][Full Text] [Related]
31. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
Shields LBE; Gordinier ME
Gynecol Obstet Invest; 2019; 84(1):94-98. PubMed ID: 30016784
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Varga A; Piha-Paul S; Ott PA; Mehnert JM; Berton-Rigaud D; Morosky A; Yang P; Ruman J; Matei D
Gynecol Oncol; 2019 Feb; 152(2):243-250. PubMed ID: 30522700
[TBL] [Abstract][Full Text] [Related]
34. Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab.
Qing M; Zhou T; Perova T; Abraham Y; Sweeney C; Krevvata M; Zhang X; Qi M; Gao G; Kim TM; Yao M; Cho SG; Eom HS; Lim ST; Yeh SP; Kwong YL; Yoon DH; Kim JS; Kim WS; Zhou L; Attar R; Verona RI
Ann Hematol; 2024 Jun; 103(6):1989-2001. PubMed ID: 38233570
[TBL] [Abstract][Full Text] [Related]
35. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
Frenel JS; Le Tourneau C; O'Neil B; Ott PA; Piha-Paul SA; Gomez-Roca C; van Brummelen EMJ; Rugo HS; Thomas S; Saraf S; Rangwala R; Varga A
J Clin Oncol; 2017 Dec; 35(36):4035-4041. PubMed ID: 29095678
[TBL] [Abstract][Full Text] [Related]
37. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
38. [Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension].
Liu WX; Liu YP; Jin J; Wang SL; Fang H; Ren H; Song YW; Chen B; Lu NN; Li N; Tang Y; Qi SN; Tang Y; Wang WH; Li YX
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):56-62. PubMed ID: 30678418
[No Abstract] [Full Text] [Related]
39. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
40. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.
Chan TSY; Li J; Loong F; Khong PL; Tse E; Kwong YL
Ann Hematol; 2018 Jan; 97(1):193-196. PubMed ID: 28879531
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
